UBS raised the firm’s price target on Akero Therapeutics (AKRO) to $109 from $42 and keeps a Buy rating on the shares. Akero reported “strong” ...
Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...
By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can ...
BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow ...
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Akero Therapeutics Inc (AKRO) stock saw a modest uptick, ending the day at $54 which represents a slight increase of $2.53 or 4.92% from the prior close of $51.47. The stock opened at $52.48 and ...
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan ...
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...
Zacks.com on MSN2d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyAkero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.
Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback